Literature DB >> 30110587

Rationale, Opportunities, and Reality of Biosimilar Medications.

Gary H Lyman1, Robin Zon2, R Donald Harvey3.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 30110587     DOI： 10.1056/NEJMc1808348

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  2 in total

1.  Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Xian Xiao; Guixing Zhang; Binxu Sun; Chaoran Wang; Xiaoqun Wang; Fanming Kong; Yingjie Jia
Journal:  Transl Cancer Res       Date:  2022-06       Impact factor: 0.496

Review 2.  Biologic Drug Quality Assurance to Optimize HER2 + Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3.

Authors:  Diana Lüftner; Gary H Lyman; João Gonçalves; Xavier Pivot; Minji Seo
Journal:  Target Oncol       Date:  2020-08       Impact factor: 4.493
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.